4D-150 IVT + Aflibercept IVT
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetic Macular Edema
Conditions
Diabetic Macular Edema, Diabetic Retinopathy
Trial Timeline
Aug 9, 2023 → Feb 28, 2029
NCT ID
NCT05930561About 4D-150 IVT + Aflibercept IVT
4D-150 IVT + Aflibercept IVT is a phase 2 stage product being developed by 4D Molecular Therapeutics for Diabetic Macular Edema. The current trial status is active. This product is registered under clinical trial identifier NCT05930561. Target conditions include Diabetic Macular Edema, Diabetic Retinopathy.
What happened to similar drugs?
20 of 20 similar drugs in Diabetic Macular Edema were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
12
Activity
12
Company
9
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05930561 | Phase 2 | Active |
| NCT05197270 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Diabetic Macular Edema